Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 8 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 3 |
| Metabolic Disorders Therapeutics Market to 2017 - Introduction | 12 | 2 |
| Overview | 12 | 1 |
| GBI Research Report Guidance | 13 | 1 |
| Metabolic Disorders Therapeutics Market to 2017 - Market Characterization | 14 | 14 |
| Introduction | 14 | 1 |
| Revenue Forecast for the Metabolic Disorders Therapeutics Market to 2017 | 15 | 1 |
| Revenues | 15 | 1 |
| Revenue by Country | 16 | 2 |
| Generic Share | 18 | 1 |
| Annual Cost of Treatment (ACT) | 19 | 1 |
| Treatment Usage Patterns | 20 | 2 |
| Diseased Population | 22 | 1 |
| Treatment Seeking Population | 23 | 1 |
| Diagnosed Population | 24 | 1 |
| Prescription Population | 25 | 1 |
| Drivers and Restraints of the Global Metabolic Disorders Therapeutics Market | 26 | 1 |
| Drivers for the Metabolic Disorders Therapeutics Market | 26 | 1 |
| First-in-Class Drugs in the Pipeline | 26 | 1 |
| Combination Therapies Have Started Playing a Key Role in the Dyslipidemia Market | 26 | 1 |
| High Unmet Needs Exist in the Obesity Market, and Therefore Any Drug That Can Manage to Pass Through FDA Approval will be a Blockbuster | 26 | 1 |
| Restraints for the Metabolic Disorders Therapeutics Market | 27 | 1 |
| Side Effects Affecting Prescription Sales of Diabetes Drugs | 27 | 1 |
| Patent Expiries of Drugs such as Actos, Starlix and Avandia are Expected to Restrain the Growth of the Global Diabetes Therapeutics Market | 27 | 1 |
| Metabolic Disorders Therapeutics Market to 2017 - Geographical Landscape | 28 | 24 |
| Revenue Analysis by Geography | 28 | 2 |
| The US | 30 | 1 |
| Revenue | 30 | 1 |
| Annual Cost of Treatment | 31 | 1 |
| Treatment Usage Pattern | 32 | 1 |
| Diseased Population | 33 | 1 |
| Treatment Seeking Population | 34 | 1 |
| Diagnosed Population | 35 | 1 |
| Prescription Population | 36 | 1 |
| Top Five Countries of Europe | 37 | 1 |
| Revenue | 37 | 2 |
| Annual Cost of Treatment | 39 | 1 |
| Treatment Usage Pattern | 40 | 1 |
| Diseased Population | 41 | 1 |
| Treatment Seeking Population | 42 | 1 |
| Diagnosed Population | 43 | 1 |
| Prescription Population | 44 | 1 |
| Japan | 45 | 1 |
| Revenue | 45 | 1 |
| Annual Cost of Treatment | 46 | 1 |
| Treatment Usage Pattern | 47 | 1 |
| Diseased Population | 48 | 1 |
| Treatment Seeking Population | 49 | 1 |
| Diagnosed Population | 50 | 1 |
| Prescription Population | 51 | 1 |
| Metabolic Disorders Therapeutics Market to 2017 - Diabetes Market | 52 | 14 |
| Introduction | 52 | 1 |
| Market Forecasts | 52 | 2 |
| Revenue by Country | 54 | 1 |
| Generic Share | 55 | 1 |
| Annual Cost of Treatment | 56 | 1 |
| Treatment Flow Algorithm | 57 | 1 |
| Treatment Usage Patterns | 58 | 1 |
| Diseased Population | 59 | 1 |
| Treatment Seeking Population | 60 | 1 |
| Diagnosed Population | 61 | 1 |
| Prescription Population | 62 | 1 |
| Major Marketed Products | 63 | 1 |
| Drivers and Restraints of the Diabetes Market | 64 | 1 |
| Drivers of the Diabetes Market | 64 | 1 |
| First-in-Class Drugs in the Pipeline | 64 | 1 |
| Increase in Prescription of Peptide Analogs | 64 | 1 |
| Sedentary Lifestyles and Obesity to Increase Diabetes Prevalence | 64 | 1 |
| Increase in Prevalence and Treatment Seeking | 65 | 1 |
| Restraints of the Diabetes Market | 65 | 1 |
| Side Effects Affecting Prescription Sales of Diabetes Drugs | 65 | 1 |
| Patent Expiries of Drugs such as Actos, Starlix and Avandia are Expected to Restrain the Growth of the Global Diabetes Therapeutics Market | 65 | 1 |
| Metabolic Disorders Therapeutics Market to 2017 - Obesity Market | 66 | 13 |
| Introduction | 66 | 1 |
| Market Forecasts | 66 | 1 |
| Revenue by Country | 67 | 1 |
| Generic Share | 68 | 1 |
| Annual Cost of Treatment | 69 | 1 |
| Treatment Flow Algorithm | 70 | 1 |
| Treatment Usage Patterns | 71 | 2 |
| Diseased Population | 73 | 1 |
| Treatment Seeking Population | 74 | 1 |
| Diagnosed Population | 75 | 1 |
| Prescription Population | 76 | 1 |
| Major Marketed Products | 77 | 1 |
| Drivers and Restraints of the Obesity Market | 77 | 1 |
| Drivers of the Obesity Market | 77 | 1 |
| High Unmet Needs Exist in the Obesity Market, and Therefore any Drug that can Manage to Pass through FDA Approval will be a Blockbuster | 77 | 1 |
| Rapidly Growing Obesity Population in Major Countries Driving the Growth of the Anti-Obesity Drugs Market | 77 | 1 |
| Restraints of the Obesity Market | 78 | 1 |
| Side-Effects Associated with Anti-Obesity Drugs are Very High | 78 | 1 |
| Refusal by Healthcare Authorities to Grant Reimbursement to Anti-Obesity Drugs has Impeded Growth | 78 | 1 |
| Availability of Other Non-Therapeutic Treatments such as Herbal Treatment and Weight-Loss Treatments Detrimental to the Growth of the Global Obesity Market | 78 | 1 |
| Metabolic Disorders Therapeutics Market to 2017 - Dyslipidemia Market | 79 | 11 |
| Introduction | 79 | 1 |
| Market Forecasts | 79 | 1 |
| Revenue by Country | 80 | 1 |
| Generic Share | 81 | 1 |
| Annual Cost of Treatment | 82 | 1 |
| Treatment Flow Algorithm | 83 | 1 |
| Treatment Usage Patterns | 84 | 1 |
| Diseased Population | 85 | 1 |
| Treatment Seeking Population | 86 | 1 |
| Diagnosed Population | 87 | 1 |
| Prescription Population | 88 | 1 |
| Major Marketed Products | 89 | 1 |
| Drivers and Restraints of the Dyslipidemia Market | 89 | 1 |
| Drivers of the Dyslipidemia Market | 89 | 1 |
| Combination Therapies Have Started Playing a Key Role in the Dyslipidemia Market | 89 | 1 |
| Restraints of the Dyslipidemia Market | 89 | 1 |
| The Dyslipidemia Market will Undergo a Significant Decline Due to the Patent Expiry of the Major Blockbuster Drug Lipitor | 89 | 1 |
| Metabolic Disorders Therapeutics Market to 2017 - Pipeline Analysis | 90 | 41 |
| Introduction | 90 | 2 |
| Diabetes: Research and Development Pipeline | 92 | 1 |
| Overview | 92 | 1 |
| Pipeline by Clinical Phases of Development | 92 | 1 |
| Pre-Clinical/Discovery | 92 | 4 |
| Phase I | 96 | 4 |
| Phase II | 100 | 4 |
| Phase III | 104 | 3 |
| NDA/Filed Molecules | 107 | 1 |
| Obesity: Research and Development Pipeline | 108 | 1 |
| Overview | 108 | 1 |
| Pipeline by Clinical Phases of Development | 108 | 1 |
| Pre-Clinical/Discovery | 108 | 3 |
| Phase I | 111 | 1 |
| Phase II | 112 | 1 |
| Phase III | 112 | 1 |
| NDA/Filed Molecules | 112 | 1 |
| Dyslipidemia: Research and Development Pipeline | 113 | 1 |
| Overview | 113 | 1 |
| Pipeline by Clinical Phases of Development | 114 | 1 |
| Pre-Clinical/Discovery | 114 | 1 |
| Phase I | 115 | 1 |
| Phase II | 115 | 2 |
| Phase III | 117 | 1 |
| Profiles of Promising Drugs in the Diabetes Market | 118 | 1 |
| rhGAD65 (Diamyd) | 118 | 1 |
| Introduction | 118 | 1 |
| Mechanism of Action | 118 | 1 |
| Clinical Trial Management | 118 | 1 |
| DiaPep277 | 119 | 1 |
| Introduction | 119 | 1 |
| Mechanism of Action | 119 | 1 |
| Clinical Trial Management | 119 | 1 |
| Otelixizumab | 119 | 1 |
| Introduction | 119 | 1 |
| Mechanism of Action | 119 | 1 |
| Clinical Trial Management | 120 | 1 |
| BMS-512148 (dapagliflozin) | 120 | 1 |
| Introduction | 120 | 1 |
| Mechanism of Action | 120 | 1 |
| Clinical Trial Management | 120 | 1 |
| D-Tagatose | 121 | 1 |
| Introduction | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| Clinical Trial Management | 121 | 1 |
| JNJ-28431754 (canagliflozin) | 121 | 1 |
| Introduction | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| Clinical Trial Management | 122 | 1 |
| Teplizumab | 122 | 1 |
| Introduction | 122 | 1 |
| Mechanism of Action | 122 | 1 |
| Clinical Trial Management | 122 | 1 |
| Lixisenatide | 123 | 1 |
| Introduction | 123 | 1 |
| Mechanism of Action | 123 | 1 |
| Clinical Trial Management | 123 | 1 |
| Profiles of Promising Drugs in the Obesity Market | 124 | 1 |
| Contrave (Buropion SR + Naltrexone) | 124 | 1 |
| Introduction | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| Clinical Trial Management | 124 | 1 |
| Victoza (liraglutide) | 124 | 1 |
| Introduction | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| Clinical Trial Management | 125 | 1 |
| Cametor (cetilistat) | 126 | 1 |
| Introduction | 126 | 1 |
| Mechanism of Action | 126 | 1 |
| Clinical Trial Management | 126 | 1 |
| Profiles of Promising Drugs in the Dyslipidemia Market | 127 | 1 |
| RG1658 (Dalcetrapib, JTT-705, RO4607381) | 127 | 1 |
| Introduction | 127 | 1 |
| Mechanism of Action | 127 | 1 |
| Clinical Trial Management | 127 | 1 |
| MK-0524A (Cordaptive, niacin + laropiprant) | 128 | 1 |
| Introduction | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| Clinical Trial Management | 128 | 1 |
| AMR101 (LAX-101, Miraxion) | 129 | 1 |
| Introduction | 129 | 1 |
| Mechanism of Action | 129 | 1 |
| Clinical Trial Management | 129 | 1 |
| MK-0859 (anacetripib) | 130 | 1 |
| Introduction | 130 | 1 |
| Mechanism of Action | 130 | 1 |
| Clinical Trial Management | 130 | 1 |
| Metabolic Disorders Therapeutics Market to 2017 - Competitive Landscape | 131 | 11 |
| Company Profiles for Metabolic Disorders | 131 | 1 |
| Pfizer Inc. | 131 | 1 |
| Company Overview | 131 | 1 |
| Business Overview | 132 | 1 |
| SWOT Analysis | 132 | 1 |
| Novo Nordisk | 133 | 1 |
| Company Overview | 133 | 1 |
| Business Overview | 133 | 1 |
| SWOT Analysis | 134 | 1 |
| Sanofi | 134 | 1 |
| Company Overview | 134 | 1 |
| Business Overview | 135 | 1 |
| SWOT Analysis | 135 | 1 |
| Takeda | 136 | 1 |
| Company Overview | 136 | 1 |
| Business Overview | 136 | 1 |
| SWOT Analysis | 136 | 1 |
| Eli Lilly | 137 | 1 |
| Company Overview | 137 | 1 |
| Business Overview | 137 | 1 |
| SWOT Analysis | 138 | 1 |
| GlaxoSmithKline (GSK) | 138 | 1 |
| Company Overview | 138 | 1 |
| Business Overview | 138 | 1 |
| SWOT Analysis | 139 | 1 |
| Merck &Co Inc | 139 | 1 |
| Company Overview | 139 | 1 |
| Business Overview | 139 | 1 |
| SWOT Analysis | 140 | 1 |
| Amylin Pharmaceuticals | 141 | 1 |
| Company Overview | 141 | 1 |
| Business Overview | 141 | 1 |
| SWOT Analysis | 141 | 1 |
| Metabolic Disorders Therapeutics Market to 2017 - Strategic Consolidations | 142 | 20 |
| Mergers and Acquisitions | 142 | 1 |
| Segmentation by Indication | 142 | 3 |
| Segmentation by Deal Value | 145 | 2 |
| Segmentation by Geography | 147 | 1 |
| Co-Development Deals | 148 | 3 |
| Summary of Co-Development Deals | 151 | 1 |
| Eli Lilly Enters into Co-Development Agreement with Boehringer Ingelheim in 2011 | 151 | 1 |
| Takeda Pharmaceutical Enters into Co-Development Agreement with Kyoto University in 2011 | 152 | 1 |
| The MOLLY and LINDSEY Diabetes Research Foundation Enters into an Agreement with the Diabetes Research Institute in 2011 | 152 | 1 |
| Sanford-Burnham and Florida Hospital Enters into Co-Development Agreement with Takeda Pharmaceutical in 2011 | 153 | 1 |
| Takeda Enters into Co-Development Agreement with Covance in 2011 | 153 | 1 |
| Takeda Enters into Co-Development Agreement with Quintiles in 2011 | 153 | 1 |
| Spencer Pharmaceutical Enters into Co-Development Agreement with Polyvalor in 2011 | 154 | 1 |
| Otsuka Pharmaceutical Factory Enters into Research Collaboration with Living Cell Technologies for DIABECELL in 2011 | 154 | 1 |